3,480 Shares in BeOne Medicines Ltd. – Sponsored ADR $ONC Purchased by True Light Capital Pte. Ltd.

True Light Capital Pte. Ltd. acquired a new position in BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 3,480 shares of the company’s stock, valued at approximately $1,057,000. BeOne Medicines accounts for approximately 0.5% of True Light Capital Pte. Ltd.’s investment portfolio, making the stock its 8th biggest position.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Daiwa Securities Group Inc. acquired a new stake in BeOne Medicines in the second quarter worth about $35,000. CWM LLC increased its position in BeOne Medicines by 32.8% in the fourth quarter. CWM LLC now owns 158 shares of the company’s stock worth $48,000 after purchasing an additional 39 shares during the period. Farther Finance Advisors LLC increased its position in BeOne Medicines by 21.8% in the fourth quarter. Farther Finance Advisors LLC now owns 218 shares of the company’s stock worth $66,000 after purchasing an additional 39 shares during the period. EverSource Wealth Advisors LLC acquired a new stake in BeOne Medicines in the second quarter worth about $68,000. Finally, Signaturefd LLC increased its position in BeOne Medicines by 10.7% in the fourth quarter. Signaturefd LLC now owns 340 shares of the company’s stock worth $103,000 after purchasing an additional 33 shares during the period. 48.55% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at BeOne Medicines

In other news, SVP Chan Henry Lee sold 341 shares of BeOne Medicines stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $300.00, for a total transaction of $102,300.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In the last quarter, insiders sold 1,005 shares of company stock worth $308,907. Insiders own 6.19% of the company’s stock.

BeOne Medicines Price Performance

Shares of ONC opened at $293.09 on Tuesday. The company has a current ratio of 3.64, a quick ratio of 3.27 and a debt-to-equity ratio of 0.20. BeOne Medicines Ltd. – Sponsored ADR has a 1 year low of $228.93 and a 1 year high of $385.22. The stock has a market cap of $32.16 billion, a P/E ratio of 65.57 and a beta of 0.50. The stock’s 50-day moving average price is $300.42 and its two-hundred day moving average price is $321.61.

BeOne Medicines (NASDAQ:ONC) last issued its earnings results on Wednesday, April 1st. The company reported $0.25 earnings per share (EPS) for the quarter. BeOne Medicines had a return on equity of 12.06% and a net margin of 8.94%.The firm had revenue of $1.51 billion for the quarter. On average, equities analysts predict that BeOne Medicines Ltd. – Sponsored ADR will post 5.65 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts recently commented on ONC shares. Leerink Partners lifted their price objective on BeOne Medicines from $364.00 to $367.00 and gave the stock an “outperform” rating in a research report on Friday. Royal Bank Of Canada raised their target price on BeOne Medicines from $423.00 to $425.00 and gave the stock an “outperform” rating in a report on Thursday, May 7th. Truist Financial restated a “buy” rating and set a $413.00 target price (up from $411.00) on shares of BeOne Medicines in a report on Thursday, May 7th. Wells Fargo & Company began coverage on BeOne Medicines in a report on Monday, May 4th. They set an “overweight” rating and a $400.00 target price on the stock. Finally, Jefferies Financial Group cut BeOne Medicines from a “buy” rating to a “hold” rating and reduced their target price for the stock from $420.00 to $290.00 in a report on Monday, March 16th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, BeOne Medicines has an average rating of “Moderate Buy” and a consensus price target of $389.15.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.